Company Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases.
It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.
The company has a license and collaboration agreement with Janssen Biotech, Inc.
Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Country | United States |
| IPO Date | Aug 11, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 126 |
| CEO | Dr. Dinesh V. Patel Ph.D. |
Contact Details
Address: 7707 Gateway Boulevard Newark, California United States | |
| Website | https://www.protagonist-inc.com |
Stock Details
| Ticker Symbol | PTGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001377121 |
| CUSIP Number | 74366E102 |
| ISIN Number | US74366E1029 |
| Employer ID | 98-0505495 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Dinesh V. Patel Ph.D. | Chief Executive Officer, President, Secretary & Director |
| Asif Ali | Executive Vice President & Chief Financial Officer |
| Carena Spivey | Head of HR & Senior Vice President of Human Resources |
| Carter J. King | Executive Vice President of Business Development |
| Dr. Ashok Bhandari Ph.D. | Executive Vice President & Chief Drug Discovery and Preclinical Development Officer |
| Dr. Mark Smythe Ph.D. | Founder & Vice President Technology |
| Dr. Newman Yeilding | EVice President, Chief Scientific Officer |
| Dr. Suneel K. Gupta Ph.D. | Executive Vice President of Clinical Development |
| Matthew M. Gosling J.D. | Executive Vice President & General Counsel |
| Mohammad Masjedizadeh Ph.D. | Executive Vice President & Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 8-K | Current Report |
| Nov 27, 2024 | 4 | Filing |